Sugi Predict

Sugi Predict / Compounds / SCHEMBL2566829

SCHEMBL2566829

SCHEMBL2566829

Cc1ccc(S(=O)(=O)OCCOC2CCOCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CYP2D6 P10635 2/20 0.40
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ CFTR P13569 1/20 0.37
▸ AOC2 O75106 1/20 0.37
▸ STAT3 P40763 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ SYK P43405 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ SLC12A2 P55011 1/20 0.35
▸ SLC12A5 Q9H2X9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004965 0.92 CA12 (0.39) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL31662482 0.92 CA12 (0.39) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL31076408 0.92 CA12 (0.41) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL31662627 0.92 CA12 (0.41) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL499873 0.90 CYP2D6 (0.44) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL7215095 0.87 ALDH1A1 (0.43) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL23210111 0.85 CA12 (0.44) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL11171926 0.85 ALDH1A1 (0.45) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL31662565 0.84 CA12 (0.40) CA12CA1CA9CYP2D6CYP1A2
SCHEMBL31662454 0.84 CYP2D6 (0.37) CYP2D6CYP1A2CYP3A4CYP2C9PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465643-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-11-11 — — US disclosed
US-20250319187-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2025-10-16 — — US disclosed
US-12409225-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-09 — — US disclosed
US-12403196-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-02 — — US disclosed
US-20250255964-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-08-14 — — US disclosed
US-20250242029-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2025-07-31 — — US disclosed
WO-2025149545-A1 HETEROARYLPHENYL ETHER DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2025-07-17 — — WO disclosed
US-20250195662-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-19 — — US disclosed
US-20250186590-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-12 — — US disclosed
US-12280113-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-04-22 — — US disclosed
CN-116457358-A Indole derivatives as RAS inhibitors for the treatment of cancer 锐新医药公司 2023-07-18 — — CN disclosed
EP-4208261-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. (US) 2023-07-12 — — EP disclosed
US-11690915-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-07-04 — — US disclosed
CN-116209438-A Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors 锐新医药公司 2023-06-02 — — CN disclosed
US-20220105185-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2022-04-07 — — US disclosed
WO-2022060836-A1 INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER Revolution Medicines, Inc. (US) 2022-03-24 — — WO disclosed
US-20130029964-A1 [5, 6] HETEROCYCLIC COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-31 — — US disclosed
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 — — EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 — — WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195662-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-20250186590-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-20250319187-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-20250255964-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-11690915-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-12403196-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES CA12 3229/4885CA1 2744/4885CA9 1117/4885
US-12465643-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-20130029964-A1 [5, 6] HETEROCYCLIC COMPOUND BMP2, BMP4, SOST CA12 2019/4885CA1 1250/4885CA9 1665/4885
US-20250242029-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-20220105185-A1 RAS INHIBITORS KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-12280113-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885
US-12409225-B2 Ras inhibitors KRAS, NRAS, HRAS CA12 4023/4885CA1 4685/4885CA9 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.